Oragenics Reports $3.07 Million Net Loss in Q3 2025, Focuses on ONP-002 Development

Oragenics, Inc. reported its financial results for the third quarter of 2025, revealing a net loss of $3.07 million for the three months ending September 30, compared to a loss of $2.46 million during the same period in 2024. For the nine months ended September 30, 2025, the company recorded a net loss of $7.56 million, slightly higher than the $7.22 million loss reported for the same period in the previous year. The increase in net loss for the quarter was attributed to higher general and administrative expenses, which rose by 40.7% to $2.19 million, primarily due to increased legal and professional fees, including a $700,000 accrual related to a legal settlement.

Total operating expenses for the third quarter of 2025 were $3.12 million, up 28.2% from $2.44 million in the prior year. Research and development expenses increased by 5.9% to $930,894, reflecting higher external research costs associated with the ONP-002 concussion program. However, for the nine-month period, R&D expenses decreased by 29.7% to $1.72 million, as the company shifted focus towards regulatory submissions and manufacturing readiness for ONP-002, resulting in lower laboratory and preclinical costs.

In terms of liquidity, Oragenics reported cash and cash equivalents of $11.4 million as of September 30, 2025, a significant increase from $864,840 at the end of 2024. This increase was primarily due to a public offering of Series H Preferred Stock and warrants completed in July 2025, which generated net proceeds of approximately $15.2 million. The company also raised $2.6 million from the sale of common stock during the nine-month period. Despite these inflows, the company continues to face substantial doubt about its ability to continue as a going concern, as it has not yet generated significant revenues and has an accumulated deficit of $224.34 million.

Operationally, Oragenics is focused on advancing its lead product candidate, ONP-002, which is intended for the treatment of mild traumatic brain injury. The company is preparing to initiate a Phase IIa clinical trial in Australia and is working on IND-enabling activities for a Phase IIb trial in the United States. The development timeline for ONP-002 includes expected starts for Phase IIa in Q4 2025 and Phase IIb in Q4 2026. The company anticipates that research and development expenses will increase as it progresses through these clinical trials.

Looking ahead, Oragenics plans to continue seeking additional capital to support its operations and development activities. The company may pursue equity and debt financings, as well as strategic partnerships, to ensure sufficient funding for its ongoing projects. However, there can be no assurance that such funding will be available on favorable terms, which could impact the company's ability to execute its business strategy and advance its product candidates.